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ABSTRACT
Objective: To analyze symptoms at different times of day in patients with COPD. 
Methods: This was a multicenter, cross-sectional observational study conducted at eight 
centers in Brazil. We evaluated morning, daytime, and nighttime symptoms in patients 
with stable COPD. Results: We included 593 patients under regular treatment, of whom 
309 (52.1%) were male and 92 (15.5%) were active smokers. The mean age was 67.7 
years, and the mean FEV1 was 49.4% of the predicted value. In comparison with the 
patients who had mild or moderate symptoms, the 183 (30.8%) with severe symptoms 
were less physically active (p = 0.002), had greater airflow limitation (p < 0.001), had 
more outpatient exacerbations (p = 0.002) and more inpatient exacerbations (p = 
0.043), as well as scoring worse on specific instruments. The most common morning 
and nighttime symptoms were dyspnea (in 45.2% and 33.1%, respectively), cough (in 
37.5% and 33.3%, respectively), and wheezing (in 24.4% and 27.0%, respectively). The 
intensity of daytime symptoms correlated strongly with that of morning symptoms (r = 
0.65, p < 0.001) and that of nighttime symptoms (r = 0.60, p < 0.001), as well as with 
the COPD Assessment Test score (r = 0.62; p < 0.001), although it showed only a weak 
correlation with FEV1 (r = −0.205; p < 0.001). Conclusions: Dyspnea was more common 
in the morning than at night. Having morning or nighttime symptoms was associated 
with greater daytime symptom severity. Symptom intensity was strongly associated 
with poor quality of life and with the frequency of exacerbations, although it was weakly 
associated with airflow limitation.
Keywords: Pulmonary disease, chronic obstructive; Signs and symptoms, respiratory; 
Quality of life; Disease progression; Brazil.
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INTRODUCTION
Classically, the management of obstructive diseases 
has always been based on clinical data.(1,2) In the early 
21st century, in keeping with the proposal according to 
which spirometry became mandatory for its diagnosis,(3) 
the main international guidelines adopted a severity 
classification system of COPD based on the degree of 
FEV1 reduction.
(3) The intention was never to diminish the 
importance of clinical information; however, in practice, 
that is what happened. It is interesting to note that the 
Brazilian consensus guidelines never ceased drawing 
attention to clinical symptoms as part of patient care.(4)
In recent years, the importance of patient-based 
outcomes in clinical trials has been emphasized. This trend 
is reflected in the current global guideline that defines the 
severity of COPD based on symptoms, pulmonary function, 
and exacerbations.(5) In parallel, the drug arsenal has been 
greatly increased by the inclusion of several medications, 
delivered by various inhalation devices, with their own 
pharmacological characteristics and pharmacodynamics. 
Finally, the concept of personalized medicine proposes 
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identifying the pattern of symptoms and the treatment 
preferences of each patient.
Various articles have assessed the behavior of 
symptoms in COPD patients around the clock in 
different populations.(6-17) Most have shown that patient 
complaints are more common early in the morning. 
Other studies have drawn attention to nighttime 
symptoms, such as the one conducted in 2018 by 
Miravitlles et al.(15) in seven Latin American countries.
Given that patient behavior varies depending on 
multiple factors, such as cultural, motivational, and 
climatic factors,(18-20) it is relevant to understand the 
symptomatic profile of patients in Brazil. In this context, 
by using the same methodology applied in the study 
conducted by Miravitlles et al.,(15) the present proposal 
aims to characterize and determine the prevalence and 
severity of symptoms early in the morning, during the 
day, and at nighttime in patients with stable COPD in 
Brazil, as well as to evaluate the correlation of each 
symptom with the severity of the disease.
METHODS
The study entitled “A Study to Evaluate Symptoms Over 
24 Hours in Patients With Chronic Obstructive Pulmonary 
Disease - LASSYC Study (LASSYC-BR)”, registered 
with ClinicalTrials.gov (identifier: NCT03381560), 
was a multicenter, cross-sectional, observational, 
non-interventional study. The aim of the study was to 
characterize the prevalence and severity of symptoms 
from the beginning of regular daytime activities to 
bedtime (daytime symptoms), in the early morning 
(morning symptoms), and at nighttime in patients with 
stable COPD in Brazil. The study was conducted between 
November of 2017 and June of 2018, at eight research 
centers, distributed throughout the southeastern and 
southern regions of Brazil and detailed in the online 
Supplement (http://www.jornaldepneumologia.com.
br/detalhe_anexo.asp?id=71; Figure S1), with the 
approval of the ethics committees of each institution. 
All the patients gave written informed consent.
The patients were in outpatient follow-up and were 
included consecutively. The inclusion and exclusion criteria 
are detailed in the online Supplement (Methods S1).
The following information, obtained from medical 
records or from interviews conducted during the study 
visits, was collected from each patient: demographic 
data, lifestyle, history of smoking, comorbidities, 
dyspnea level, COPD severity, and the history of 
exacerbations in the last 12 months. Patients provided 
data on daytime, morning, and nighttime disease-related 
symptoms, as well as on health-related quality of life 
and level of physical activity.
Dyspnea level was measured using the modified 
Medical Research Council (mMRC) dyspnea scale.(21) 
The level of COPD severity was quantified using the 
Body mass index, airflow Obstruction, Dyspnea, and 
Exacerbations index (BODEx).(22) Comorbidities were 
assessed using the COPD-specific COmorbidity TEst 
(COTE) score.(23) The COPD Assessment Test (CAT) 
was utilized to define the impact of the disease on 
health status.(24) 
Daytime symptoms were assessed using the 
EXAcerbations of COPD Tool (EXACT)-Respiratory 
Symptoms (E-RS) questionnaire, designed for use in 
clinical trials to assess the effectiveness of therapeutic 
interventions regarding symptoms.(25,26) The E-RS 
evaluates symptoms that have occurred on the day 
prior to a study visit, from the beginning of regular 
activities until the patient lies down to sleep.(25) The 
E-RS provides a total score, ranging from 0 to 40, and 
three subscales: RS-dyspnea (scale 0-17); RS-cough 
and sputum (scale 0-11); and RS-symptoms in the 
chest (scale 0-12). Higher scores translate to greater 
symptom intensity.
Morning symptoms (on the day of a study visit, from 
the time patients got out of bed to begin their daytime 
activities until they were ready for routine activities) 
were analyzed using the Early Morning Symptoms of 
COPD Instrument.(27) 
Nighttime symptoms (from the time the research 
subject went to bed the night before until rising out of 
bed to begin daytime activities on the day of a study 
visit) were measured using the Nighttime Symptoms of 
COPD Instrument (online Supplement; Methods S1).(28)
The intensity of daytime symptoms was classified as 
mild, moderate, or severe, according to the distribution 
of E-RS scores in tertiles. The questionnaire has no 
predetermined cutoff levels.
In the study conducted by Miravitlles et al.,(15) 
the presence of morning symptoms was considered 
significant in cases of moderate, intense, or very intense 
dyspnea, associated with any other moderate, intense, 
or very intense symptoms (definition 1). To evaluate the 
influence of different definition criteria on the prevalence 
of symptoms, we also adopted a second definition: at 
least two of the evaluated symptoms classified as being 
at least moderate or one symptom perceived as being 
at least intense (definition 2). Similarly, for the analysis 
of significant nighttime symptoms, two definitions were 
considered: any nocturnal awakening (definition of the 
study conducted by Miravitlles et al.)(15); or at least two 
symptoms assessed as being at least moderate or one 
symptom perceived as being at least severe. The level 
of physical activity was assessed using the International 
Physical Activity Questionnaire.(29)
Considering the primary outcome of the study 
(the occurrence of morning, daytime, and nighttime 
symptoms), we calculated the sample size based on the 
estimated prevalence of the outcome in each period. A 
30-40% prevalence of the outcome was considered, with 
an estimated error of 5%, a confidence interval of 95%, 
and the addition of 5% for possible losses. Therefore, 
the estimated sample size required was 600 patients.
Statistical analysis
Descriptive analyses were performed to show absolute 
frequencies using the chi-square test for heterogeneity 
to describe morning, daytime, and nighttime symptoms. 
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Pearson’s correlation test was used in order to obtain 
the correlation coefficient of FEV1 symptom scores. All 
analyses were performed with the Stata statistical package, 
version 15.1 (StataCorp LP, College Station, TX, USA).
RESULTS
Patients
We included 593 patients whose demographic and 
clinical characteristics are shown in Table 1. The mean 
age was 67.7 ± 9.0 years. The mean FEV1 was 49.4% 
± 17.5% of the predicted value. In the sample, 92 
patients (15.5%) were active smokers and 102 (17.2%) 
reported having a concomitant diagnosis of asthma. 
The complete results of the questionnaires concerning 
symptoms were available for 565 patients.
Patient characteristics according to 
daytime symptoms
There was a balance in the distribution of patients 
regarding mild, moderate, and severe daytime 
symptoms. Compared with the mild and moderate 
symptoms groups, the severe respiratory symptoms 
group had higher proportions of patients with a low 
level of physical activity (p = 0.002), greater dyspnea 
severity on the mMRC scale (p < 0.001), greater 
airflow limitation. (p < 0.001), worse CAT scores, and 
worse BODEx scores (p < 0.001 for both), as well 
as a higher prevalence of outpatient and inpatient 
exacerbations in the last year (p = 0.002 and p = 
0.043, respectively; Table 1).
Prevalence and intensity of morning and 
nighttime symptoms
The most common symptoms were dyspnea, cough, 
and wheezing (Figure 1). The prevalence of morning and 
nighttime symptoms was similar, except for dyspnea. 
In the sample as a whole, the morning symptoms were 
cough, in 37.5% of the patients; wheezing, in 24.4%; 
dyspnea, in 45.2%; chest tightness, in 15.7%; chest 
congestion, in 20.6%; and difficulty expelling phlegm, 
in 17.5%. The nighttime symptoms were cough, in 
33.3% of the patients; wheezing, in 27.0%; dyspnea, 
in 33.1%; chest tightness, in 18.3%; chest congestion, 
in 19.5%; and difficulty expelling phlegm, in 18.8%. 
Although most symptoms were described as mild or 
moderate, approximately 10% of patients rated their 
dyspnea as severe or very severe (in the morning, in 
10.1%; and at night, in 8.5%).
Of the 593 patients in the sample, 120 (20%) 
reported moderate, intense, or very intense dyspnea 
associated with any other moderate, intense, or very 
intense morning symptom (definition 1). Regarding 
nighttime symptoms, 107 (18%) patients reported 
at least one nocturnal awakening due to symptoms 
associated with COPD.
In relation to definition 2 (at least two of the 
symptoms assessed as being at least moderate or 
one perceived as being at least intense), 182 (31%) 
and 171 (29%) patients had significant morning and 
nighttime symptoms, respectively.
Characteristics of patients with morning or 
nighttime symptoms
Patients who reported moderate, intense, or very 
intense dyspnea associated with any other moderate, 
intense, or very intense morning symptom (definition 1) 
were younger, had higher COTE, mMRC, CAT, and BODEx 
scores, and reported a higher number of outpatient 
exacerbations in the last year (p < 0.001 for all).
Patients who reported nocturnal awakening due to 
COPD (definition 1) were younger, had higher mMRC 
scores, and had higher CAT scores (p < 0.001 for all), 
as well as having higher BODEx scores (p = 0.001; 
Table 2).
Using the criteria of definition 2, we observed the 
following (online supplement; Table S1): patients with 
morning symptoms were younger (p < 0.001); were 
predominantly male (p = 0.022); had higher COTE, 
mMRC, CAT, and BODEx scores (p < 0.001 for all); 
had worse pulmonary function, as determined by FEV1 
(p = 0.015); and had a higher number of outpatient 
exacerbations in the past year (p < 0.001).
Patients with nighttime symptoms were younger (p 
= 0.039); were predominantly female (p = 0.044); 
had higher COTE and mMRC scores (p = 0.013 and 
p < 0.001, respectively); had worse CAT and BODEx 
scores (p < 0.001 for both); had a higher number of 
outpatient exacerbations in the past year (p < 0.001); 
and had a higher number of inpatient exacerbations 
in the past year (p = 0.021). Pulmonary function 
did not differ between the patients with and without 
nighttime symptoms.
Association between the intensity of 
daytime symptoms and the presence of 
morning and nighttime symptoms 
We detected a strong association between the 
presence of morning and nighttime symptoms and the 
intensity of daytime symptoms using definition 1. Of 
the patients with morning symptoms, 76.1% reported 
severe daytime symptoms, compared with only 21.4% 
of those without morning symptoms. Similarly, 64.7% 
of the patients with nighttime symptoms reported 
severe daytime symptoms, compared with only 25.3% 
of those without nighttime symptoms. Among those 
with morning and nighttime symptoms, approximately 
90% had severe daytime symptoms, compared with 
less than 20% of those with no morning or nighttime 
symptoms (Figure 2). The same level of association 
was detected by analyses using definition 2 (online 
Supplement; Figure S2).
Correlations between the intensity of daytime 
symptoms and the presence of morning and 
nighttime symptoms, as well as COPD characteristics
The correlation matrix between some COPD 
characteristics and the overall E-RS score is presented 
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in Table 3. All but one of the variables had a correlation 
close to or greater than 0.6 (moderate to high), including 
the global E-RS—CAT score (r = 0.62; p < 0.001), the 
severity score of morning symptoms (r = 0.65; p < 
0.001), and the severity score of nighttime symptoms 
(r = 0.60; p < 0.001), the exception being pulmonary 
function (r = −0.21; p < 0.001). In addition, the CAT 
score correlated well with the severity of morning and 
nighttime symptoms. We also observed a very strong 
correlation between morning and nighttime symptom 
severity scores (r = 0.83; p < 0.001).
Patients with a concomitant diagnosis of asthma were 
younger, were mostly female, and had a higher body 
mass index. Except for those characteristics and the 
FVC in % of predicted value, there were no statistical 
differences in any other parameter.
DISCUSSION
We have shown that a considerable proportion of 
patients with stable COPD remain symptomatic. The 
strong association between morning and nighttime 
complaints, as well as the intensity of symptoms 
during the day, suggest that the symptoms affect 
the clinical behavior of the disease around the clock. 
Those results indicate that a focused history-taking 
investigating this variability may help in defining an 
individualized therapeutic proposal.













Age, years 67.7 ± 9.0 69.1 ± 9.0 67.3 ± 9.1 66.2 ± 8.4 0.003 0.133 0.003 0.707
Male 309 (52.1) 121 (56.2) 89 (53.6) 81 (44.3) 0.052 0.640 0.019 0.081
BMI, kg/m2 26.4 ± 5.3 26.3 ± 4.8 26.3 ± 5.5 26.6 ± 5.7 0.781 1.000 1.000 1.000
Active smokers 92 (15.5) 30 (13.9) 31 (18.7) 23 (12.6) 0.243 0.206 0.699 0.115
Smoking history, pack-years 51.2 ± 32.9 50.9 ± 35.3 48.7 ± 28.8 53.8 ± 33.3 0.338 1.000 1.000 0.431
Levels of physical activity 0.002 0.040 0.001 0.172
Low 233 (39.3) 66 (30.6) 62 (37.4) 86 (47.0)
Moderate 131 (22.1) 44 (20.4) 44 (26.5) 38 (20.8)
High 229 (38.6) 106 (49.1) 60 (36.1) 59 (32.2)
Diagnosis of asthma 102 (17.2) 39 (18.1) 27 (16.3) 34 (18.6) 0.839 0.646 0.893 0.570
COTE index 1.3 ± 2.3 1.0 ± 1.9 1.3 ± 2.4 1.6 ± 2.5 0.052 0.694 0.045 0.777
mMRC scale 2.1 ± 1.1 1.5 ± 0.9 2.2 ± 1.1 2.7 ± 0.9 < 0.001 < 0.001 < 0.001 < 0.001
Spirometry
FVC, % of predicted 70.9 ± 16.4 74.9 ± 16.1 70.0 ± 16.5 67.3 ± 16.3 < 0.001 0.012 < 0.001 0.363
FEV1, % of predicted 49.4 ± 17.5 54.3 ± 16.7 48.0 ± 17.9 44.8 ± 17.2 < 0.001 0.001 < 0.001 0.264
FEV1/FVC 50.9 ± 11.3 53.1 ± 10.7 49.9 ± 11.4 48.7 ± 11.6 < 0.001 0.016 < 0.001 0.937
CAT score 16.8 ± 8.5 10.8 ± 5.9 17.8 ± 7.3 22.7 ± 7.5 < 0.001 < 0.001 < 0.001 < 0.001
BODEx index 2.9 ± 1.8 2.0 ± 1.4 3.1 ± 1.8 3.7 ± 1.7 < 0.001 < 0.001 < 0.001 0.001
Exacerbations
Outpatient 0.9 ± 2.4 0.6 ± 1.1 0.8 ± 1.2 1.4 ± 3.9 0.002 1.000 0.002 0.044
Inpatient 0.2 ± 0.5 0.1 ± 0.3 0.1 ± 0.4 0.2 ± 0.5 0.043 0.905 0.037 0.526
E-RS score
Total 8.9 ± 7.3 1.5 ± 1.4 8.9 ± 2.4 17.7 ± 4.1 < 0.001 < 0.001 < 0.001 < 0.001
Breathlessness domain 6.4 ± 6.0 0.6 ± 1.1 6.6 ± 3.9 13.3 ± 3.2 < 0.001 < 0.001 < 0.001 < 0.001
Cough and sputum 
domain
1.6 ± 1.9 0.7 ± 1.0 1.6 ± 1.9 2.8 ± 2.1 < 0.001 < 0.001 < 0.001 < 0.001
Chest symptoms domain 0.8 ± 1.2 0.2 ± 0.5 0.7 ± 0.9 1.6 ± 1.5 < 0.001 < 0.001 < 0.001 < 0.001
Severity of morning 
symptoms score
3.0 ± 3.8 0.7 ± 1.4 3.0 ± 2.9 5.7 ± 4.7 < 0.001 < 0.001 < 0.001 < 0.001
Severity of nighttime 
symptoms score
2.9 ± 4.0 0.7 ± 1.6 2.6 ± 3.5 5.6 ± 4.7 < 0.001 < 0.001 < 0.001 < 0.001
≥ 1 nocturnal awakening 
due to COPD
107 (18.0) 12 (5.6) 24 (14.5) 66 (36.1) < 0.001 0.003 < 0.001 < 0.001
BMI: body mass index; COTE: (COPD-specific) COmorbidity TEst; mMRC: modified Medical Research Council score; 
CAT: COPD Assessment Test; BODEx: Body mass index, airflow Obstruction, Dyspnea, and Exacerbations; and 
E-RS: EXAcerbations of COPD Tool (EXACT)-Respiratory Symptoms. aValues expressed in n (%) or mean ± SD. 
bComplete data from 565 patients. Incomplete data from 28 patients. *ANOVA for continuous variables and the 
chi-square test for categorical variables.
J Bras Pneumol. 2020;46(3):e201902234/9
Cukier A, Godoy I, Costa CH, Rubin AS, Gregorio MG, Albuquerque Neto AA, Lima MA, 
Pereira MC, Tanni SE, Athanazio RA, Bessa EJC, Wehrmeister FC, Lourenco CB, Menezes AMB
Thirty percent of patients with stable COPD 
undergoing regular clinical treatment reported severe 
daytime symptoms. A considerable number reported 
morning symptoms or nocturnal awakening due 
to respiratory complaints. Dyspnea was the most 
common manifestation, being 12% more common in 
the morning than at night, and 10% of the patients 
rated their dyspnea as intense or very intense.
Our results were similar to those obtained in the 
study conducted by Miravitlles et al.,(15) despite the 
predominance of men in that study (61% vs. 52%) 
and a higher prevalence of asthma in our population 
(17.2% vs. 4.5%). Recently, Soler-Cataluña et al.(14) 
reported that symptoms and their impact on quality 
of life were less pronounced among patients in Spain 
than among those in other European countries. The 
higher proportion of men in the Spanish cohort was 
hypothesized to be one of the possible explanations 
for the difference, because it has been suggested that 
the impact of COPD would be greater in women.(30) 
Regarding asthma, its symptomatic behavior in our 
patients did not differ in relation to the 82.8% of patients 
who did not have an associated diagnosis of asthma 
and COPD, suggesting that asthma did not influence 
the pattern of variability in respiratory complaints.
In recent years, several authors have published 
studies evaluating the variability of symptoms in patients 
with stable COPD in different regions.(6-17) Morning 
symptoms were reported by 37-81% of the patients 
in the samples, whereas nighttime symptoms were 
reported by 25-68%. There are several explanations 
for this disparity, such as the heterogeneity in study 
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Figure 1. Prevalence and intensity of morning symptoms (in A) and nighttime symptoms (in B). 
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behavioral differences between patients in different 
locations.(18,19,32)
By adopting two forms of grading symptoms, we 
demonstrated the importance of the assessment 
method in determining their prevalence. Morning 
dyspnea was reported by 20% of our patients when 
the criterion was moderate, intense, or very intense 
dyspnea accompanied by any other moderate, intense, 
or very intense symptom. This prevalence increased to 
31% by simply changing the criteria to include at least 
two symptoms assessed as being at least moderate 
or one perceived as being at least intense. Similarly, 
the prevalence of nighttime symptoms varied between 
18% and 29% due to the change of those two criteria, 
respectively.
Morning and nighttime symptoms were both found 
to correlate strongly with the intensity of symptoms 
around the clock. We also observed a very strong 
correlation between morning and nighttime symptom 
severity scores. However, the correlation between 
symptoms and the degree of airflow limitation, although 
statistically significant, was weak. Those data are in line 
with those of other publications,(6-17) which underscores 
the importance of assessing the symptomatology of 
patients and the weak association between the degree 
of spirometric changes and symptoms.
One of the strengths of our study was that we 
characterized the symptomatic behavior of COPD patients 
in Brazil with an adequate sample size. Regarding the 
methodological aspects, we emphasize that the present 
study is one of the few in the international literature in 
which validated questionnaires were used to evaluate 
morning and nighttime symptoms.(31)
Our study has some limitations. As with all other 
published studies on the variability of symptoms around 
the clock, we emphasize that this was a cross-sectional 
Table 2. Demographic and clinical characteristics of COPD patients, according to the presence of morning or nighttime 
symptoms.a,b
Characteristic Morning symptoms p* Nighttime symptoms p*
No Yes No Yes 
(n = 473) (n = 120) (n = 486) (n = 107)
Age, years 68.3 ± 9.1 65.3 ± 8.3 < 0.001 68.3 ± 8.9 64.9 ± 9.0 < 0.001
Male 255 (53.9) 54 (45.0) 0.081 258 (53.1) 51 (47.7) 0.309
BMI, kg/m2 26.3 ± 5.1 26.7 ± 5.9 0.475 26.4 ± 5.1 26.4 ± 6.2 0.962
Active smokers 73 (15.4) 19 (15.8) 0.914 74 (15.2) 18 (16.8) 0.680
Smoking history, pack-years 50.3 ± 33.4 54.7 ± 30.4 0.187 51.0 ± 33.4 52.1 ± 30.3 0.761
Levels of physical activity 0.633 0.314
Low 182 (38.5) 51 (42.5) 184 (37.9) 49 (45.8)
Moderate 104 (22.0) 27 (22.5) 110 (22.6) 21 (19.6)
High 187 (39.5) 42 (35.0) 192 (39.5) 37 (34.6)
Diagnosis of asthma 78 (16.5) 24 (20.0) 0.363 86 (17.7) 16 (15.0) 0.496
COTE index 1.1 ± 2.1 1.9 ± 2.7 < 0.001 1.3 ± 2.2 1.4 ± 2.4 0.622
mMRC scale 2.0 ± 1.1 2.6 ± 1.0 < 0.001 2.0 ± 1.1 2.4 ± 1.0 < 0.001
Spirometry
FVC, % of predicted 71.4 ± 16.1 69.0 ± 17.5 0.163 71.5 ± 16.4 67.9 ± 15.8 0.041
FEV1, % of predicted 50.0 ± 17.3 47.1 ± 18.3 0.109 49.8 ± 17.4 47.3 ± 17.7 0.176
FEV1/FVC 51.1 ± 11.5 49.7 ± 10.5 0.213 50.8 ± 11.4 50.9 ± 11.2 0.937
CAT score 14.8 ± 7.4 24.5 ± 8.0 < 0.001 15.4 ± 7.9 23.4 ± 8.0 < 0.001
BODEx index 2.7 ± 1.7 3.5 ± 1.8 < 0.001 2.8 ± 1.8 3.4 ± 1.8 0.001
Exacerbations
Outpatient 0.7 ± 1.2 1.7 ± 0.4 < 0.001 0.8 ± 2.5 1.3 ± 1.4 0.028
Inpatient 0.1 ± 0.5 0.2 ± 0.5 0.129 0.1 ± 0.5 0.2 ± 0.6 0.248
E-RS score
Total 6.8 ± 6.0 17.4 ± 6.1 < 0.001 7.6 ± 6.6 14.8 ± 7.5 < 0.001
Breathlessness domain 5.0 ± 5.5 12.0 ± 4.5 < 0.001 5.7 ± 5.8 9.9 ± 5.6 < 0.001
Cough and sputum domain 1.2 ± 1.6 3.2 ± 2.3 < 0.001 1.3 ± 1.7 3.0 ± 2.3 < 0.001
Chest symptoms domain 0.5 ± 0.8 2.0 ± 1.5 < 0.001 0.6 ± 0.9 1.8 ± 1.5 < 0.001
Severity of morning symptoms score 1.6 ± 2.0 8.7 ± 4.0 < 0.001 2.1 ± 2.8 7.0 ± 5.0 < 0.001
Severity of nighttime symptoms score 1.6 ± 2.5 7.6 ± 5.0 < 0.001 1.9 ± 3.0 7.4 ± 4.6 < 0.001
≥ 1 nocturnal awakening due to COPD 51 (10.8) 56 (46.7) < 0.001 - - -
BMI: body mass index; COTE: (COPD-specific) COmorbidity TEst; mMRC: modified Medical Research Council score; 
CAT: COPD Assessment Test; BODEx: Body mass index, airflow Obstruction, Dyspnea, and Exacerbations; and 
E-RS: EXAcerbations of COPD Tool (EXACT)-Respiratory Symptoms. aValues expressed in n (%) or mean ± SD. 
bComplete data from 565 patients. Incomplete data from 28 patients. *ANOVA for continuous variables and the 
chi-square test for categorical variables.
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observational analysis. In addition, as with other studies, 
we evaluated only the variability of respiratory symptoms 
without investigating extrapulmonary manifestations. 
Another limitation is related to the distribution of the 
participating research centers, all of which treat patients 
at the secondary and tertiary health care levels and 
are located in the southeastern or southern regions 
of the country, thereby limiting the generalizability 
of the findings. Finally, during the collection of data, 
there were variations in the availability of medications 
at most of those centers. Although the patients 
included in the study had not had any changes in their 
medication prescriptions for two months, some were 
not using their usual maintenance treatment regimen. 
However, these limitations did not influence the main 
study outcome, which underscores the importance of 
evaluating the variability of symptomatology around 
the clock in our population.
The mechanisms responsible for the temporal 
variability of respiratory symptoms are unclear. Circadian 
rhythms probably have an influence. In healthy 
individuals, it is recognized that FEV1 is reduced by 
approximately 150 mL during the night,(33) and a similar 
reduction has been reported in patients with COPD.(34) 
It is speculated that these variations contribute to the 
onset of nighttime and morning symptoms.
Our data have obvious clinical implications. Health 
professionals are used to questioning COPD patients 







































































































J Bras Pneumol. 2020;46(3):e20190223 7/9
Symptom variability over the course of the day in patients with stable COPD in Brazil: a real-world observational study
about their symptoms. However, it is not customary 
to ask patients to report the period of the day during 
which their complaints prevail, nor is it common 
to inquire about the impact those complaints have 
on their activities and well-being. A considerable 
proportion of patients remain symptomatic despite 
receiving adequate treatment that follows the 
treatment guidelines. It is possible that, for some, a 
personalized approach to treatment that recognizes 
the particularities of the periods of the day during 
which the symptoms are at their worst will result in 
an improvement of symptoms.
When we treat our patients, we use a set of 
information. Specifically, we evaluate and quantify 
their symptoms, the frequency and intensity of 
exacerbations, the behavior of the disease over time, 
and the impact on activities of daily living.(35) The data 
presented in this study, combined with those published 
previously, suggest that inquiring about the variability 
of symptoms throughout the day and night should be 
an integral part of a proper history-taking.
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Table 3. Correlation matrix between the total score of the global EXAcerbations of COPD Tool-Respiratory Symptoms 
instrument, COPD Assessment Test score, FEV1 in % of predicted, and severity scores of morning and nighttime symptoms.
Parameter E-RS total CAT FEV1, % of 
predicted value
Score – morning 
symptoms
r p r p r p r p
CAT 0.6176 < 0.001
FEV1, % of predicted value −0.2095 < 0.001 −0.1923 < 0.001
Morning symptoms score 0.6515 < 0.001 0.5857 < 0.001 −0.0428 0.310
Nighttime symptoms score 0.5982 < 0.001 0.5833 < 0.001 −0.0051 0.904 0.8334 < 0.001
E-RS: EXAcerbations of COPD Tool (EXACT)-Respiratory Symptoms; and CAT: COPD Assessment Test.
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